Bromhexine Safety in Second Trimester
Bromhexine can likely be continued during the second trimester of pregnancy, as the available evidence suggests it does not increase the risk of major birth defects, though data remain limited and mucolytics should be used when maternal benefit justifies potential unknown fetal risks.
Evidence-Based Recommendation
The 2020 ERS/TSANZ guidelines on airways disease management in pregnancy explicitly state that "routine therapy with inhaled bronchodilators, corticosteroids, antibiotics and mucolytics should continue to maintain maternal stability throughout pregnancy" for women with bronchiectasis and cystic fibrosis 1. This guideline establishes the principle that mucolytics as a class are acceptable when needed for maternal respiratory stability.
Key Supporting Data
Birth Defect Risk Assessment
The most relevant and recent evidence comes from a 2024 multicenter prospective cohort study examining ambroxol (the active metabolite of bromhexine) exposure during first trimester—the period of highest teratogenic risk 2. This study found:
- No increased risk of major birth defects with first-trimester ambroxol exposure (aOR: 1.1,95% CI: 0.18-7.2, p = 0.88)
- Incidence of major defects was 2.1% in the ambroxol group versus 1.7% in controls
- No specific pattern of birth defects emerged
Since second trimester exposure carries lower teratogenic risk than first trimester (organogenesis is complete), and ambroxol showed no signal even during the critical first trimester period, second trimester use appears reasonably safe.
Clinical Decision Framework
When to use bromhexine in second trimester:
- Maternal respiratory condition requires mucolytic therapy for adequate secretion clearance
- Benefits of maintaining maternal respiratory stability outweigh theoretical fetal risks
- Alternative non-pharmacologic measures are insufficient
Important caveats:
- Limited human pregnancy data exists specifically for bromhexine (most data is for its metabolite ambroxol)
- Historical studies from 1978-1982 examined ambroxol for fetal lung maturation without identifying safety concerns 3, 4
- The guideline framework emphasizes that "the use of any drugs during pregnancy needs to balance the maternal risk of therapy versus no therapy and the fetal risk of uncontrolled maternal disease" 1
Practical Considerations
The principle established in the airways disease guideline is critical: maternal hypoxia and uncontrolled respiratory disease pose well-documented risks to the fetus 1. If bromhexine is necessary to maintain adequate airway clearance and prevent maternal respiratory compromise, continuing it in the second trimester is justified.
Monitor for maternal therapeutic response and adjust only if ineffective, rather than discontinuing due to pregnancy alone.